• HOME |
  • SITE MAP |
Product Search
since 1897 R&D visual


  • About R&D
  • Research Achievements
  • Organization of research institute
  • Key Research Area
  • R&D Pipeline
  • Technical Innovation Network
  • Global Dong Wha

News of R&D

A new quinolone antibiotic

1. Name of product

Zrumgil (zabofloxacin)

2. Potential advantages

1) More active than any other Quinolones (in vitro, in vivo)

2) Highly active against respiratory tract pathogen (G(+) - S.pneumoniae, S.aureus, S.pyogenes and M.catarrhalis)

3) Good safety profile (in mouse, rat and dog)

4) No phototoxicity

3. Characteristics

New fluoroquinolone antimicrobial agents(Zabofloxacin, DW224) has broad antibacterial activities. It has also excellent activities against RTI pathogen. In preclinical and clinical studies, it has established a good safety profile.

4. Progress

Final stage of phase III clinical trial

Go to TOP

6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, 04522, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.